NEXMED INC (WKN: 914164 / NEXM) / Nasdaq
NexMed Announces the Ability of the NexACT® Technology to Deliver Drugs Orally and with Enhanced Bioavailability
Date : 01/12/2010 @ 1:51PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/...pid=nmona&article=41075942&symbol=NEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete
Dr. Bassam Damaj, NexMed’s Chief Executive Officer stated, “The results from these proof of concept studies are exciting and support our belief that NexACT can be successfully used to enhance oral bioavailability of a broad range of drugs, which could include our proprietary drug candidates, generic drugs and proprietary drugs owned by others who are developing second-generation formulations to provide extended patent protection with increased convenience and bioavailability. Our ability to leverage our proprietary NexACT technology in this way is expected to provide exciting new development opportunities and will no longer restrict us to the topical delivery of dermal drugs. Additional studies are ongoing to extend the validation of the technology into other classes of oral drugs.” About NexMed NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed has a proprietary product pipeline based on its NexACT drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis and wound healing. For further information, go to www.nexmed.com and www.bio-quant.com
Taxol® is a registered trademark of Bristol-Myers Squibb Company
Durch die Bio-Quant Aquisition ist NEOM >Dept-free!< - IMO ist die 1 USD-Marke keine Frage...
http://www.ariva.de/...KN_914164_NEXM_Nasdaq_t362738?page=0#jumppos24
...Also as previously announced, NexMed remains subject to a grace period through January 25, 2010 to evidence compliance with the $1.00 bid price requirement for continued listing on NASDAQ. ...
dank im vorraus
von daher, mache deine DD selber (ich denke, man soll nur auf seine eigene ... hören?)
nexm.png (verkleinert auf 37%)
brauchst doch nicht gleich eingeschnappt sein :)
gruß doc
p.s werd heut nochmal nachlegen.
cu
19.01.2010 20:02
NexMed Updates on Canadian Aproval Process for Vitaros
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, announced today that it received a Notice of Non-Compliance ("Notice") as part of the review process from Health Canada for its New Drug Submission ("NDS") for the Vitaros erectile dysfunction treatment filed in February 2008. The deficiencies cited related to the product's CMC (Chemistry, Manufacturing and Controls). There were no pre-clinical or clinical deficiencies cited in the Notice. The Notice is a routine end-of-review communication from Health Canada when additional information is needed to reach final decision on product approval.
Dr. Bassam Damaj, NexMed's Chief Executive Officer said, "The Notice provides us with a clear pathway to obtaining marketing approval of the product in Canada. The FDA had previously raised most of Health Canada's CMC issues and we were successful in working out a compliance plan with them. We look forward to discussing Health Canada's specific concerns in a face-to face meeting which will be our first since we filed the NDS. In the meantime, we remain optimistic about the approvability of our Vitaros product in Canada."
The normal process of follow up to the Notice is that NexMed has 90 days from the date of the Notice to respond to Health Canada, followed by the Health Canada 45 day screening process in the Regulatory Project Management group and then a 150 day review cycle by the NDS reviewers.
About NexMed
NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization ("CRO") based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed also has a proprietary product pipeline based on its NexACT drug delivery technology. For further information, go to www.nexmed.com and www.bio-quant.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that the Company will successfully resolve the issues identified by Health Canada in the Notice or that Vitaros will receive marketing approval from Health Canada or other regulatory body.
Contacts:
NexMed:
NexMed, Inc.
Ed Cox, 858-926-5811
VP- IR
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
© 2010 Business Wire
wenn ich das richtig gelesen habe schmeissen die sehr viele neue aktien auf denMarkt oder ?
siehe hier :
http://ih.advfn.com/...4440958&article=41244053&symbol=N^NEXM
für Nexmed bedeutet ?
Besten dank im voraus.
Gruß und schönen Abend.
hm mein english ist glaube ich dafür dann doch zu schwach. verstehe da im Moment nur Bahnhof. Muss ich mir morgen in aller Ruhe mal zur Gemüte ziehen vlt. kann ich das besser verstehen als auf die schnelle.
Kleine Hilfestellung deinerseits könnte aber schon helfen. Wenn nicht auch nicht schlimm muss ich mich morgen mal durchbeissen
http://www.finanznachrichten.de/...ontinued-listing-on-nasdaq-004.htm
NexMed Granted Request for Continued Listing on NASDAQ
Company Required to Hold Annual Meeting by May 24, 2010 and Evidence Bid Price of at Least $1.00 per share for Minimum of Ten Business Days by July 15, 2010
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that the NASDAQ Listing Qualifications Panel (the "Panel") has determined that NexMed has evidenced compliance with the market value of listed securities requirement for continued listing on The NASDAQ Capital Market by evidencing a market capitalization in excess of $35 million for a minimum of ten consecutive trading days, in lieu of the $2.5 million in stockholder's equity as required by the Panel's decision dated December 17, 2009. In its recent determination, the Panel also granted NexMed's request for an extension through May 24, 2010 to solicit proxies and hold its 2009/2010 Annual Meeting and thereby evidence compliance with NASDAQ's proxy solicitation and annual meeting requirements. In addition, the Panel has granted the Company's request for an extension through July 15, 2010 to evidence compliance with NASDAQ's minimum bid price requirement of $1.00 per share. On January 26, 2010, NexMed was notified by the NASDAQ Listing Qualifications Staff that the Company no longer satisfied the minimum bid price requirement. The Company was provided with the opportunity to present its plan to regain compliance with that requirement for the Panel's review and did so on January 27, 2010.
Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "We are very pleased with the Panel's decision to grant us the extension and we are committed to taking the actions needed to meet the remaining requirements for continued listing. The progress we have made with NASDAQ is the first step in executing our new growth strategy for 2010 and beyond."
About NexMed
NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed also has a proprietary product pipeline based on its NexACT® drug delivery technology. For further information, go to www.nexmed.com and www.bio-quant.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, its ability to maintain its Nasdaq listing requirement and other matters that are outside the control of the Company.
Contacts:
NexMed Contacts:
NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
© 2010 Business Wire
1
|